Viatris Inc. (VTRS) fair value analysis
S&P 500 · Updated 2026-10-19
VTRS price how computed
Valuation status
Awaiting full valuationVTRS does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards.
We require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $17.64
- Sector
- Healthcare
- 12-month range
- $10.11–$18.66
- Market cap
- $20.3B
- From 52-week high
- -5.4%
- Shares outstanding
- 1.15B
- Rank in Healthcare by quality score
- #140 of 301
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Viatris Inc. is a global pharmaceutical company that develops, manufactures, and distributes generic and branded medicines across multiple therapeutic areas. The company operates in markets throughout North America, Europe, Asia, and other regions worldwide.
VTRS currently ranks #140 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $20.3B
- P/E (trailing)
- 7x
- Revenue (TTM)
- $14.7B
- Net margin
- -2.8%
- EPS (TTM)
- $2.52
- Gross margin
- 38.8%
- Debt / equity
- 0.96
- Revenue growth (3-yr avg)
- -1.6%
- Shares outstanding
- 1.15B
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Contracting
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 70 · neutral
- 50-day average
- $16.98
- 200-day average
- $15.60
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $0.48 per share (4 payments)
- Yield on last price
- 2.72%
- Consecutive years of increases
- 0 (no streak on complete calendar years)
- Last ex-dividend date
- 2026-08-21
- Last payment date
- 2026-09-16
Earnings how computed
- Next earnings report
- 2026-11-05 (pre-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+11.3%)
2026-03 ▲ beat (+18.0%)
2025-12 ▲ beat (+9.6%)
2025-09 ▲ beat (+8.1%)
2025-06 ▲ beat (+10.7%)
2025-03 ▲ beat (+2.0%)
2024-12 ▼ miss (-5.6%)
2024-09 ▲ beat (+10.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 4 hold · 1 sell (12 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $19.7
- Target vs last price
- +11.7%
What our data shows for VTRS
- Our model validated 2 trailing price-to-earnings windows for VTRS, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $10.11–$18.66.
- The 14-day relative strength index sits at a neutral 70.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- VTRS's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent VTRS news
TickrTrends' derived news-sentiment signal for VTRS is currently leaning positive, computed from recent coverage.
- Viatris Inc (VTRS): What a GF Score of 63 Says About the Stock (gurufocus.com, 2026-10-20)
- Viatris’ Dividend Has Room to Grow, but Will Management Deliver? (insidermonkey.com, 2026-10-19)
- Viatris (VTRS) Gains FDA Approval for Ryzumvi to Treat Presbyopia (gurufocus.com, 2026-10-16)
More VTRS news
- Viatris Inc (VTRS) Shares Surge 4.5% -- What GF Score of 63 Tells Investors (gurufocus.com, 2026-10-15)
- Viatris: Is The Pacira Deal A Game Changer? (Rating Upgrade) (NASDAQ:VTRS) (seekingalpha.com, 2026-10-12)
- Viatris To Acquire Pacira BioSciences - What Investors Should Know (NASDAQ:VTRS) (seekingalpha.com, 2026-10-09)
- Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff? (insidermonkey.com, 2026-10-08)
What people are saying
Follow the VTRS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is VTRS stock undervalued?
VTRS does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is VTRS's TickrTrends verdict?
VTRS is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does VTRS compare to other Healthcare stocks?
VTRS ranks #140 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is VTRS overbought or oversold?
VTRS's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does VTRS pay a dividend?
Yes. VTRS paid $0.48 per share over the last twelve months (4 payments), a 2.72% yield on TickrTrends' last price. The last ex-dividend date was 2026-08-21.
When does VTRS report earnings next?
VTRS's next earnings report is scheduled for 2026-11-05 (pre-market), per the published earnings calendar.
Does VTRS usually beat earnings estimates?
Over its last 8 reported quarters VTRS beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about VTRS?
Of 12 analysts covering VTRS, 7 rate it a buy, 4 a hold and 1 a sell - buy-leaning, with a consensus price target of $19.7 (+11.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.